BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25023248)

  • 1. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies.
    Kesselheim AS; Bykov K; Avorn J; Tong A; Doherty M; Choudhry NK
    Ann Intern Med; 2014 Jul; 161(2):96-103. PubMed ID: 25023248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence.
    Kesselheim AS; Misono AS; Shrank WH; Greene JA; Doherty M; Avorn J; Choudhry NK
    JAMA Intern Med; 2013 Feb; 173(3):202-8. PubMed ID: 23277164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age.
    Setoguchi S; Glynn RJ; Avorn J; Levin R; Winkelmayer WC
    Am J Cardiol; 2007 Oct; 100(7):1061-7. PubMed ID: 17884362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of drug combinations on admission for recurrent myocardial infarction.
    van der Elst ME; Bouvy ML; de Blaey CJ; de Boer A
    Heart; 2007 Oct; 93(10):1226-30. PubMed ID: 17502329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
    Björck L; Wallentin L; Stenestrand U; Lappas G; Rosengren A
    Arch Intern Med; 2010 Aug; 170(15):1375-81. PubMed ID: 20696964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
    Austin PC; Tu JV; Ko DT; Alter DA
    CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
    Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
    Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care.
    Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C
    J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis.
    Setoguchi S; Glynn RJ; Avorn J; Mittleman MA; Levin R; Winkelmayer WC
    J Am Coll Cardiol; 2008 Apr; 51(13):1247-54. PubMed ID: 18371553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
    Shrank WH; Hoang T; Ettner SL; Glassman PA; Nair K; DeLapp D; Dirstine J; Avorn J; Asch SM
    Arch Intern Med; 2006 Feb; 166(3):332-7. PubMed ID: 16476874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC; Alfaddagh A; Zubaid M; Rashed W; Ridha M; Alenezi F; Alhamdan R; Akbar M; Bulbanat BY; Al-Suwaidi J
    Int J Cardiol; 2013 Aug; 167(4):1406-11. PubMed ID: 22578736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization.
    Tuppin P; Neumann A; Danchin N; de Peretti C; Weill A; Ricordeau P; Allemand H
    Arch Cardiovasc Dis; 2010; 103(6-7):363-75. PubMed ID: 20800800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of kidney function with cardiovascular medication use after myocardial infarction.
    Winkelmayer WC; Levin R; Setoguchi S
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1415-22. PubMed ID: 18614775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
    O'Brien EC; McCoy LA; Thomas L; Peterson ED; Wang TY
    Am Heart J; 2015 Jul; 170(1):55-61. PubMed ID: 26093864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes.
    Choudhry NK; Glynn RJ; Avorn J; Lee JL; Brennan TA; Reisman L; Toscano M; Levin R; Matlin OS; Antman EM; Shrank WH
    Am Heart J; 2014 Jan; 167(1):51-58.e5. PubMed ID: 24332142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.